Epidarex is an early-stage life sciences investor headquartered in Edinburgh, with an office in the U.S. The firm invests in and builds high-growth life science companies, often partnering with leading medical universities and research institutions. Epidarex focuses on addressing major unmet disease needs, including in oncology, inflammation, cardiometabolic and neuroscience.
Reason for commitment from British Business Bank
The British Business Bank first invested in 2020 with a £50m cornerstone commitment to Epidarex Capital III UK LP.
Aligns with the Bank’s strategy to support the UK’s most promising companies in the life sciences sector. Also supports the Bank’s strategic objective to unlock potential in people and places by building high-growth companies across the UK, including emerging research hubs outside of the South East.
Previous investments by the manager
Enterprise Therapeutics, Apellis Pharmaceuticals (Nasdaq:APLS), Nodthera, Mironid Therapeutics, AdoRx, Leucid Bio, Epsilogen, Kynos, Macomics, Lario Therapeutics, Harpoon Medical, Libra Therapeutics and Theolytics.
Epidarex Fund IV has completed full British Business Bank due diligence, and received Investment Committee approval.
-
Fund Manager
Epidarex Capital
-
Based in
Edinburgh
-
Stage
Seed & Series A
-
Industrial Strategy Sectors
Life Sciences
-
Structure
GP/LP
-
Fundraising target
£200 million
-
British Business Bank Commitment
£50 million - January 2026
Disclaimer
This website includes information about UK investment funds in which one or more entities within the British Business Bank group (“BBB Group”) may be investors. This information is provided for information purposes only – it has no regard to the specific investment objectives or particular needs of any person and does not constitute an offer, recommendation, or financial promotion under applicable legislation. The BBB Group does not market or make investment opportunities available to the public. Fund details are provided by external sources and the BBB Group does not verify their accuracy. Fund investments involve significant risk, including the risk of losing capital.
Access to this website is intended for authorised persons only. Users are responsible for complying with local laws and regulations regarding access. Any investment enquiries must be directed to the relevant fund manager and any investment decisions must be based solely on information provided by the relevant fund or fund manager.